Company news
Marker Therapeutics, Inc. news in 2022
Marker Therapeutics, Inc.'s news releases, calls and decks from 2022, newest first.
Marker Therapeutics and Lincoln Park Capital Enter into a Common Stock Purchase Agreement for up to $25 Million
December 12, 2022
Marker Therapeutics Announces FDA Clearance of IND for MT-601, its Six-Antigen T Cell Therapy for the Treatment of Pancreatic Cancer
November 21, 2022
Marker Therapeutics Reports Q3 2022 Operating and Financial Results
November 9, 2022
Marker Therapeutics Awarded $2 Million Grant from U.S. FDA to Support Marker’s Phase 2 ARTEMIS Trial of MT-401 in Post-Transplant AML
September 12, 2022
Marker Therapeutics to Participate in Cantor Fitzgerald Cell and Genetic Medicines Conference
September 7, 2022
Marker Therapeutics Reports Q2 2022 Operating and Financial Results
August 10, 2022
Marker Therapeutics Announces FDA Clearance of IND for MT-601, the six-antigen targeted T Cell Therapy for the treatment of relapsed/refractory Non-Hodgkin Lymphoma
August 3, 2022
Marker Therapeutics Reports Q1 2022 Operating and Financial Results
May 12, 2022
Marker Therapeutics to Present Four Posters on its T Cell-Based Immunotherapies at the 2022 International Society for Cell & Gene Therapy Annual Meeting
May 3, 2022
Marker Therapeutics Announces Entry into Services Agreement with Wilson Wolf
April 25, 2022
Marker Therapeutics Reports Fiscal Year 2021 Operating and Financial Results
March 16, 2022
Marker Therapeutics to Present at Two Upcoming March Investor Conferences
March 6, 2022
Marker Therapeutics Announces Clinical Program Updates and Pipeline Expansion
February 15, 2022
Marker Therapeutics to Host Clinical Program Update Conference Call and Webcast on Wednesday, February 16, 2022
February 7, 2022
Marker Therapeutics Receives FDA Orphan Drug Designation for its Multi-Antigen Targeted T Cell Therapy for Pancreatic Cancer
January 18, 2022